Morgan Stanley’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-339,922
| Closed | -$16.1M | – | 8205 |
|
|
2025
Q3 | $16.1M | Sell |
339,922
-353,334
| -51% | -$17.1M | ﹤0.01% | 3087 |
|
|
2025
Q2 | $37M | Sell |
693,256
-109,598
| -14% | -$4.98M | ﹤0.01% | 2196 |
|
|
2025
Q1 | $32.5M | Buy |
802,854
+331,319
| +70% | +$14M | ﹤0.01% | 2205 |
|
|
2024
Q4 | $13.1M | Buy |
471,535
+23,465
| +5% | +$711K | ﹤0.01% | 3150 |
|
|
2024
Q3 | $12.9M | Sell |
448,070
-498,458
| -53% | -$13M | ﹤0.01% | 3228 |
|
|
2024
Q2 | $22.2M | Buy |
946,528
+542,665
| +134% | +$11.6M | ﹤0.01% | 2546 |
|
|
2024
Q1 | $10.2M | Sell |
403,863
-1,710,791
| -81% | -$41.1M | ﹤0.01% | 3333 |
|
|
2023
Q4 | $49.4M | Buy |
2,114,654
+1,674,918
| +381% | +$33M | ﹤0.01% | 2470 |
|
|
2023
Q3 | $22.2M | Buy |
439,736
+54,078
| +14% | +$2.52M | ﹤0.01% | 2336 |
|
|
2023
Q2 | $18M | Buy |
385,658
+28,065
| +8% | +$1.29M | ﹤0.01% | 2585 |
|
|
2023
Q1 | $13.7M | Buy |
357,593
+150,593
| +73% | +$6.71M | ﹤0.01% | 2845 |
|
|
2022
Q4 | $11.3M | Buy |
207,000
+13,747
| +7% | +$589K | ﹤0.01% | 2951 |
|
|
2022
Q3 | $6.58M | Buy |
193,253
+54,050
| +39% | +$827K | ﹤0.01% | 3423 |
|
|
2022
Q2 | $1.32M | Sell |
139,203
-27,848
| -17% | -$290K | ﹤0.01% | 4833 |
|
|
2022
Q1 | $2.37M | Buy |
167,051
+97,627
| +141% | +$1.71M | ﹤0.01% | 4386 |
|
|
2021
Q4 | $1.47M | Buy |
69,424
+12,175
| +21% | +$270K | ﹤0.01% | 4809 |
|
|
2021
Q3 | $1.28M | Sell |
57,249
-32,354
| -36% | -$732K | ﹤0.01% | 4890 |
|
|
2021
Q2 | $2.22M | Buy |
89,603
+59,413
| +197% | +$1.67M | ﹤0.01% | 4543 |
|
|
2021
Q1 | $876K | Buy |
30,190
+1,404
| +5% | +$42.5K | ﹤0.01% | 4819 |
|
|
2020
Q4 | $743K | Buy |
28,786
+21,699
| +306% | +$604K | ﹤0.01% | 4834 |
|
|
2020
Q3 | $219K | Sell |
7,087
-128,503
| -95% | -$4.49M | ﹤0.01% | 5064 |
|
|
2020
Q2 | $3.38M | Buy |
135,590
+134,315
| +10,535% | +$3.07M | ﹤0.01% | 3070 |
|
|
2020
Q1 | $27K | Sell |
1,275
-5,390
| -81% | -$116K | ﹤0.01% | 5702 |
|
|
2019
Q4 | $148K | Buy |
6,665
+5,003
| +301% | +$104K | ﹤0.01% | 5521 |
|
|
2019
Q3 | $38K | Buy |
1,662
+1,562
| +1,562% | +$36.3K | ﹤0.01% | 5820 |
|
|
2019
Q2 | $2K | Buy |
+100
| New | +$1.9K | ﹤0.01% | 6448 |
|
Other funds holding AKRO
Morgan Stanley's AKRO Position: Q4 2025 in Review
Morgan Stanley sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 339,922 shares — an estimated $16.1M sold.
Morgan Stanley first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $49.4M in Q4 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Morgan Stanley reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Morgan Stanley sold 339,922 Akero Therapeutics shares in Q4 2025, an estimated $16.1M.
- Morgan Stanley first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- Morgan Stanley's Akero Therapeutics position peaked at $49.4M in Q4 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.